CN109380723A - 一种安神助眠食品及其制备方法 - Google Patents
一种安神助眠食品及其制备方法 Download PDFInfo
- Publication number
- CN109380723A CN109380723A CN201811309311.0A CN201811309311A CN109380723A CN 109380723 A CN109380723 A CN 109380723A CN 201811309311 A CN201811309311 A CN 201811309311A CN 109380723 A CN109380723 A CN 109380723A
- Authority
- CN
- China
- Prior art keywords
- parts
- added
- extract
- hops
- mixing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000007958 sleep Effects 0.000 title claims abstract description 50
- 235000013305 food Nutrition 0.000 title claims abstract description 33
- 230000003340 mental effect Effects 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 241000229143 Hippophae Species 0.000 claims abstract description 47
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 47
- 239000000284 extract Substances 0.000 claims abstract description 47
- 239000000843 powder Substances 0.000 claims abstract description 26
- 238000002156 mixing Methods 0.000 claims abstract description 25
- 235000008694 Humulus lupulus Nutrition 0.000 claims abstract description 23
- 244000025221 Humulus lupulus Species 0.000 claims abstract description 22
- 238000000855 fermentation Methods 0.000 claims abstract description 20
- 230000004151 fermentation Effects 0.000 claims abstract description 20
- 241000894006 Bacteria Species 0.000 claims abstract description 17
- 241000218231 Moraceae Species 0.000 claims abstract description 17
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 17
- QWLHYYKDLOVBNV-UHFFFAOYSA-L magnesium orotate Chemical compound [Mg+2].[O-]C(=O)C1=CC(=O)NC(=O)N1.[O-]C(=O)C1=CC(=O)NC(=O)N1 QWLHYYKDLOVBNV-UHFFFAOYSA-L 0.000 claims abstract description 14
- 229960000407 magnesium orotate Drugs 0.000 claims abstract description 14
- 230000002936 tranquilizing effect Effects 0.000 claims abstract description 14
- 244000197580 Poria cocos Species 0.000 claims abstract description 11
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 11
- 210000000582 semen Anatomy 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 31
- 238000000605 extraction Methods 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 14
- 241000234435 Lilium Species 0.000 claims description 13
- 235000019441 ethanol Nutrition 0.000 claims description 10
- 235000013336 milk Nutrition 0.000 claims description 8
- 239000008267 milk Substances 0.000 claims description 8
- 210000004080 milk Anatomy 0.000 claims description 8
- 239000004310 lactic acid Substances 0.000 claims description 7
- 235000014655 lactic acid Nutrition 0.000 claims description 7
- 235000015097 nutrients Nutrition 0.000 claims description 7
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 6
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000005416 organic matter Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 241001251949 Xanthium sibiricum Species 0.000 claims 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract description 21
- 238000000034 method Methods 0.000 abstract description 8
- 230000001430 anti-depressive effect Effects 0.000 abstract description 6
- 239000000935 antidepressant agent Substances 0.000 abstract description 5
- 229940005513 antidepressants Drugs 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 5
- 229940076279 serotonin Drugs 0.000 abstract description 5
- 208000019116 sleep disease Diseases 0.000 abstract description 5
- 208000022925 sleep disturbance Diseases 0.000 abstract description 5
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 230000000975 bioactive effect Effects 0.000 abstract description 3
- 230000036578 sleeping time Effects 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 2
- 230000003860 sleep quality Effects 0.000 abstract description 2
- 229930003270 Vitamin B Natural products 0.000 abstract 1
- 235000019156 vitamin B Nutrition 0.000 abstract 1
- 239000011720 vitamin B Substances 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 9
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 9
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 7
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 7
- 206010022437 insomnia Diseases 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 206010002869 Anxiety symptoms Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 102000040350 B family Human genes 0.000 description 2
- 108091072128 B family Proteins 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229940091250 magnesium supplement Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 2
- 229960003987 melatonin Drugs 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 230000037053 non-rapid eye movement Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000004461 rapid eye movement Effects 0.000 description 2
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- MVAUGMLUJKTORM-UHFFFAOYSA-N Licoricidin Natural products COc1cc2OCC(Cc2cc1CC=C(C)C)c3ccc(O)c(CC=C(C)C)c3O MVAUGMLUJKTORM-UHFFFAOYSA-N 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 1
- 229940093767 glabridin Drugs 0.000 description 1
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 1
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- GBRZTUJCDFSIHM-KRWDZBQOSA-N licoricidin Chemical compound C1([C@@H]2COC=3C=C(O)C(CC=C(C)C)=C(C=3C2)OC)=CC=C(O)C(CC=C(C)C)=C1O GBRZTUJCDFSIHM-KRWDZBQOSA-N 0.000 description 1
- GBRZTUJCDFSIHM-UHFFFAOYSA-N licorisoflavan B Natural products C1C=2C(OC)=C(CC=C(C)C)C(O)=CC=2OCC1C1=CC=C(O)C(CC=C(C)C)=C1O GBRZTUJCDFSIHM-UHFFFAOYSA-N 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000004617 sleep duration Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 230000008454 sleep-wake cycle Effects 0.000 description 1
- 230000037322 slow-wave sleep Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000021081 unsaturated fats Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Anesthesiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种安神助眠食品及其制备方法,属于保健食品技术领域;原料包括:沙棘籽、酸枣仁、啤酒花、茯苓、桑葚、乳清酸镁、菌粉;将啤酒花有机提取物浸膏中加入茯苓后与沙棘籽和酸枣仁的有机提取物混合,加入桑葚和乳清酸镁,再次混合后加入菌粉进行发酵3‑5d后干燥得到成品;本发明含有多种改善睡眠的生物活性成分,维生素B6以及5‑羟色胺的含量显著提升,具有镇静、安神和促进睡眠的作用,本发明采用了抗抑郁治疗的方法,从根本上改善睡眠障碍,提高睡眠质量,延长睡眠时间。
Description
技术领域
本发明属于保健食品技术领域,具体涉及一种经过微生物发酵的安神助眠抗抑郁的保健食品及其制备方法。
背景技术
随着社会化进程的加速,人们面对的各种压力越来越大,接受的外界刺激越来越多,由此引发的失眠和抑郁症逐年上升。睡眠受中枢神经系统的主动调节,与中枢神经递质的作用密切相关。人类睡眠相关的神经递质主要有γ-氨基丁酸(γ-aminobutyric acid,GABA)、5-羟色胺(5-hydroxytryptamine,5-HT)、乙酰胆碱(acetylcholine,Ach)等。GABA系统广泛分布于大脑和小脑,参与睡眠-觉醒周期的调节,是抑制性递质系统。5-HT递质系统位于大脑的特定部位,尤其是大脑边缘系统,参与情绪、行为、记忆等多种生理功能的调控。5-HT是褪黑激素的前体物质,可阻止或缩短REM睡眠(快速眼球运动(rapid eye movement,REM)睡眠),增加慢波睡眠;GABA可延长NREM睡眠(非快速眼球运动(non rapid eyemovement,NREM)睡眠),Ach能激发REM睡眠。而目前大多数用于治疗失眠的药物以GABA(A)受体为靶点,如苯二氮卓类药物、巴比妥类药物等。但是这些药物往往导致药物耐受、成瘾等不良反应,须按照《麻醉药品和精神药品管理条例》进行严格管控。
5-羟色胺可参与控制情绪、焦虑,调节睡眠、痛觉等。多种心理性因素引起脑内5-羟色胺含量降低,从而导致抑郁、焦虑等常见的心境障碍。当大脑5-羟色胺含量减少时可出现睡眠障碍,抑郁症状,注意力不集中,记忆力下降,自责和内疚,以及焦虑症状,并经常紧张、不安、心烦、易怒、恐惧、多虑等,因此,失眠往往是焦虑抑郁的表现症状。在西医治疗方面,对于抑郁症和失眠的治疗往往没有结合治疗,单纯针对失眠或者抑郁症治疗,只能是治标不治本。
从沙棘籽中提取的沙棘籽油富含多种生物活性成份,其中含有的苹果酸、草酸等有机酸,以及黄酮、维生素C、维生素E、不饱和脂肪酸、甾醇等活性成分,对癌症、心脑血管疾病、高血压、高血脂以及肝脏疾病等具有较好的预防或治疗作用,而沙棘籽油在神经和精神系统疾病特别是抑郁症方面的作用尚未见文献报道。
发明内容
本发明克服现有技术的不足,提供了一种安神助眠食品及其制备方法,本发明是通过如下技术方案实现的。
一种安神助眠食品,包括以下重量份的原料:沙棘籽20-40份、酸枣仁10-30份、啤酒花30-50份、茯苓5-8份、桑葚40-60份、乳清酸镁0.5-0.8份、菌粉0.4-0.6份。
优选的,还包括以下重量份的原料:百合40-60份、牛奶40-60份、决明子8-12份、安神菜2-4份、甘草2-4份。
优选的,所述的菌粉为干酵母粉、酵母营养素和乳酸菌粉的一种或其任意组合。
一种安神助眠食品的制备方法,包括以下步骤:
a)将所述的沙棘籽和酸枣仁用有机物提取得到沙棘籽提取物混合浸膏。
b)将啤酒花用有机物提取得到啤酒花提取物浸膏,在所述啤酒花提取物浸膏中加入茯苓,得到啤酒花提取混合物。
c)将沙棘籽提取物混合浸膏和啤酒花提取混合物搅拌均匀后,加入桑葚和乳清酸镁,混合后加入菌粉进行发酵3-5d后干燥得到成品。
作为优选的方式,所述的步骤a中得到的沙棘籽提取物混合浸膏中加入安神菜和甘草得到沙棘籽提取混合物,将沙棘籽提取混合物和啤酒花提取混合物搅拌均匀后,加入桑葚和乳清酸镁,混合后加入菌粉进行发酵3-5d后干燥得到成品。
作为优选方式,将所述的安神菜和甘草隔水蒸制50-60min,干燥粉碎后与沙棘籽提取物混合浸膏混合后得到沙棘籽提取混合物。
作为优选方式,将沙棘籽提取物混合浸膏和啤酒花提取混合物搅拌均匀后,加入桑葚、百合和乳清酸镁。
作为优选的,所述的有机物提取是采用乙醇提取。
本产品通过沙棘籽、酸枣仁、决明子和啤酒花提取物,再加入安神菜、甘草、茯苓、百合和桑葚,再掺入乳清酸镁、牛奶、干酵母粉、酵母营养素、乳酸菌粉等进行发酵,然后干燥,粉碎制得的食品。该食品中含有多种改善睡眠的生物活性成分,包括长链不饱和脂肪酸、多种B族维生素、多种微量元素、百合总皂苷、羧甲基茯苓多糖、茯苓总三萜类化合物、光甘草定、2- 甲基 -3- 丁烯 -2- 醇,以及多种生物碱和总黄酮类物质等,都具有镇静、安神和促进睡眠的作用,本方剂采用了抗抑郁治疗的方法,从根本上改善睡眠障碍,提高睡眠质量,延长睡眠时间。
本发明相对于现有技术所产生的有益效果为。
沙棘籽提取物中含有有机酸,以及黄酮、维生素C、维生素E、不饱和脂肪酸、甾醇等活性成分,以沙棘籽、酸枣仁提取物与啤酒花提取物为主要成分通过发酵产生大量的B族维生素,其中维生素B6更为重要,当人类深度睡眠时,GABA含量会升高,实验表明有维生素B6时,GABA提高,人较易入眠深睡。故要让亢奋的脑细胞休息,除用褪黑激素外,还得加上维生素B6始能发挥良好功能。
在复配安神菜、甘草、茯苓、百合、决明子和桑葚的原料中,经过微生物的发酵,产生的发酵产物中5-羟色胺的成分明显提高。在5-羟色胺的作用下,明显降低睡眠障碍和抑郁症状,以及焦虑症状,在缓解了失眠症状的前提下,起到抗抑郁的效果,通过调节5-羟色胺功能,从根本上改善上述睡眠障碍、抑郁症和焦虑症状,所以,本产品对于失眠病人的治疗,采用了抗抑郁治疗的方法。
具体实施方式
为了使本发明所要解决的技术问题、技术方案及有益效果更加清楚明白,结合实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。下面结合实施例详细说明本发明的技术方案,但保护范围不被此限制。
实施例1
一种安神助眠食品的制备方法,具体步骤如下:
1)取沙棘籽300g,酸枣仁200g,决明子100g,混合后在60℃干燥,粉碎,过60目筛,50—70%乙醇提取,加入乙醇的量按重量比是物料︰乙醇=1︰10,80℃保温2h,并搅拌,将滤液滤出。提取2次,将2次滤液合并,将乙醇回收,并浓缩至膏状,比重(相对密度)1.3,得沙棘籽提取物混合浸膏。
2)取安神菜30g,甘草30g,上蒸锅蒸1h,80℃烘干,粉碎,过80目筛,得安神甘草粉。
3)将上述步骤2中的安神甘草粉60g加入步骤1中的沙棘籽提取物混合浸膏中,搅拌,80℃烘干,粉碎,过80目筛,得沙棘籽提取混合物。
4)取啤酒花400g,60℃干燥,粉碎,过60目筛,50—70%乙醇提取,加入乙醇的量按重量比是物料︰乙醇=1︰10,80℃保温2h,并搅拌,将滤液滤出。提取2次,将2次滤液合并,将乙醇回收,并浓缩至膏状,比重(相对密度)1.3,得啤酒花提取物浸膏。
5)将茯苓60g,粉碎,过60目筛,并加入步骤4所得啤酒花提取物浸膏中,搅拌,80℃烘干,粉碎,过80目筛,得啤酒花提取混合物。
6)鲜百合500g,鲜桑葚500g,用高速捣碎机粉碎,再加入白糖200g,柠檬酸4g,乳清酸镁6g,牛奶500g,或乳酸菌粉5g,或干酵母粉 5g和酵母营养素5g,然后加入沙棘籽提取混合物和啤酒花提取混合物,搅拌,加水调和到能形成团状,并用手能挤压出水,25℃-37℃保温发酵,发酵时间是3天,发酵过程中要搅拌6-10次,发酵完成后80℃干燥,粉碎,过80目筛,既得沙棘助睡眠食品,压片,或胶囊均可。
实施例2
一种安神助眠食品的制备方法,具体步骤如下:
取鲜百合400g,鲜桑葚600g,用高速捣碎机粉碎,再加入白糖200g,柠檬酸4g,乳清酸镁5g,牛奶500g,干酵母粉 5g和酵母营养素5g,加入沙棘籽提取混合物和啤酒花提取混合物,加水调和到能形成团状,并用手能挤压出水,37℃保温发酵5天,发酵过程中搅拌10次,发酵完成后80℃干燥,粉碎,过80目筛,既得沙棘助睡眠食品,压片,或胶囊均可。其中所述的沙棘籽提取混合物和啤酒花提取混合物的制备方法与实施例1相同。
实施例3
鲜百合600g,鲜桑葚400g,用高速捣碎机粉碎,再加入白糖200g,柠檬酸4g,乳清酸镁6g,牛奶500g,乳酸菌粉5g,加入沙棘籽提取混合物和啤酒花提取混合物,加水调和到能形成团状,并用手能挤压出水,27℃保温发酵3天,发酵过程中搅拌6次,发酵结束后80℃干燥,粉碎,过80目筛,既得沙棘助睡眠食品,压片,或胶囊均可。其中所述的沙棘籽提取混合物和啤酒花提取混合物的制备方法与实施例1相同。
实施例4
鲜百合500g,鲜桑葚500g,用高速捣碎机粉碎,再加入白糖200g,柠檬酸4g,乳清酸镁6g,牛奶500g,乳酸菌粉5g,干酵母粉 5g,酵母营养素5g,加入沙棘籽提取混合物和啤酒花提取混合物,加水调和到能形成团状,并用手能挤压出水,30℃保温发酵5天,发酵过程中搅拌10次,发酵结束后80℃干燥,粉碎,过80目筛,既得沙棘助睡眠食品,压片,或胶囊均可。其中所述的沙棘籽提取混合物和啤酒花提取混合物的制备方法与实施例1相同。
活性功能实验:
按照国家《保健食品检验与评价技术规范》中的“改善睡眠功能检验方法”的要求,对本发明实施例1所制备的安神助眠抗抑郁的食品进行了改善睡眠活性功能实验,其结果如下。
表1、沙棘助睡眠食品的直接催眠作用的结果。
注:与正常对照组比较,*p﹤0.05,**P﹤0.01,
由表1可见,与空白组相比中剂量组已经具有了催眠作用,高剂量组几乎与安定有相同的效果。
表2、沙棘助睡眠食品与阈下剂量戊巴比妥钠协同作用对小鼠入睡率测定结果。
注:与正常对照组比较,**P﹤0.01。
由表2可见,各剂量组均对小鼠入睡率显著增强,低剂量组的效果和安定组睡眠药相同,高剂量组的入睡率是安定组的两倍,有明显的剂量依赖性。
表3、沙棘助睡眠食品与阈上剂量戊巴比妥钠协同作用延长小鼠睡眠持续时间测定的测定结果。
注:与正常对照组比较,*p﹤0.05,**P﹤0.01,
由表3可见,与空白组相比其他各剂量组都能延长小鼠持续睡眠时间,沙棘助睡眠食品的各剂量组均具有显著性,各剂量组的效果均优于安定组。
表4、沙棘助睡眠食品与阈上剂量戊巴比妥钠协同作用缩短小鼠睡眠潜伏时间测定结果。
注:与正常对照组比较,*p﹤0.05,**P﹤0.01。
由表4可见,沙棘助睡眠食品各剂量组均能缩短小鼠睡眠的潜伏时间,与安定组的效果相似,且中剂量组效果最佳。
本产品通过沙棘籽、酸枣仁、决明子和啤酒花提取物,再加入安神菜、甘草、茯苓、百合和桑葚,再掺入白糖、柠檬酸、乳清酸镁、牛奶、干酵母粉、酵母营养素、乳酸菌粉等进行发酵,然后干燥,粉碎制得的食品。该食品中含有多种改善睡眠的生物活性成分,包括长链不饱和脂肪酸、多种B族维生素、多种微量元素、百合总皂苷、羧甲基茯苓多糖、茯苓总三萜类化合物、光甘草定、2- 甲基 -3- 丁烯 -2- 醇,以及多种生物碱和总黄酮类物质等,都具有镇静、安神和促进睡眠的作用,本方剂采用了抗抑郁治疗的方法,从根本上改善睡眠障碍,提高睡眠质量,延长睡眠时间。
以上内容是结合具体的优选实施方式对本发明所做的进一步详细说明,不能认定本发明的具体实施方式仅限于此,对于本发明所属技术领域的普通技术人员来说,在不脱离本发明的前提下,还可以做出若干简单的推演或替换,都应当视为属于本发明由所提交的权利要求书确定专利保护范围。
Claims (8)
1.一种安神助眠食品,其特征在于,包括以下重量份的原料:沙棘籽20-40份、酸枣仁10-30份、啤酒花30-50份、茯苓5-8份、桑葚40-60份、乳清酸镁0.5-0.8份、菌粉0.4-0.6份。
2.根据权利要求1所述的一种安神助眠食品,其特征在于,还包括以下重量份的原料:百合40-60份、牛奶40-60份、决明子8-12份、安神菜2-4份、甘草2-4份。
3.根据权利要求1或2所述的一种安神助眠食品,其特征在于,所述的菌粉为干酵母粉、酵母营养素和乳酸菌粉的一种或其任意组合。
4.如权利要求1所述的一种安神助眠食品的制备方法,其特征在于,包括以下步骤:
a)将所述的沙棘籽和酸枣仁用有机物提取得到沙棘籽提取物混合浸膏;
b)将啤酒花用有机物提取得到啤酒花提取物浸膏,在所述啤酒花提取物浸膏中加入茯苓,得到啤酒花提取混合物;
c)将沙棘籽提取物混合浸膏和啤酒花提取混合物搅拌均匀后,加入桑葚和乳清酸镁,混合后加入菌粉进行发酵3-5d后干燥得到成品。
5.根据权利要求4所述的一种安神助眠食品的制备方法,其特征在于,所述的步骤a中得到的沙棘籽提取物混合浸膏中加入安神菜和甘草得到沙棘籽提取混合物,将沙棘籽提取混合物和啤酒花提取混合物搅拌均匀后,加入桑葚和乳清酸镁,混合后加入菌粉进行发酵3-5d后干燥得到成品。
6.根据权利要求5所述的一种安神助眠食品的制备方法,其特征在于,将所述的安神菜和甘草隔水蒸制50-60min,干燥粉碎后与沙棘籽提取物混合浸膏混合后得到沙棘籽提取混合物。
7.根据权利要求4所述的一种安神助眠食品的制备方法,其特征在于,将沙棘籽提取物混合浸膏和啤酒花提取混合物搅拌均匀后,加入桑葚、百合和乳清酸镁。
8.根据权利要求4所述的一种安神助眠食品的制备方法,其特征在于,所述的有机物提取是采用乙醇提取。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811309311.0A CN109380723A (zh) | 2018-11-05 | 2018-11-05 | 一种安神助眠食品及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811309311.0A CN109380723A (zh) | 2018-11-05 | 2018-11-05 | 一种安神助眠食品及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109380723A true CN109380723A (zh) | 2019-02-26 |
Family
ID=65428430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811309311.0A Pending CN109380723A (zh) | 2018-11-05 | 2018-11-05 | 一种安神助眠食品及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109380723A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112167626A (zh) * | 2020-09-30 | 2021-01-05 | 内蒙古菓奇奇沙棘生物科技股份有限公司 | 一种沙棘助眠食品及其制备方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102961462A (zh) * | 2012-11-23 | 2013-03-13 | 西安泰科迈医药科技有限公司 | 一种用于改善睡眠、改善胃肠道功能的药物组合物及其分散片制备方法 |
CN104069335A (zh) * | 2014-07-17 | 2014-10-01 | 江苏东博生物医药有限公司 | 一种改善睡眠的药物组合物及制备方法和应用 |
CN104606294A (zh) * | 2013-11-04 | 2015-05-13 | 吉林吉春制药股份有限公司 | 一种用于健胃消食,安神利尿,同时辅助治疗胃纳不香, 睡眠不安肺结核的药物及其制备方法 |
CN105267723A (zh) * | 2014-07-23 | 2016-01-27 | 华中科技大学 | 一种具有改善睡眠功效的玛咖组方及其制备方法 |
CN105394177A (zh) * | 2015-11-11 | 2016-03-16 | 西北农林科技大学 | 一种促睡眠酸乳及其制备方法 |
CN106281950A (zh) * | 2016-08-18 | 2017-01-04 | 安徽天乾健食品科技有限公司 | 一种安神助眠沙棘风味果胶醋及其制备方法 |
CN106857825A (zh) * | 2015-12-10 | 2017-06-20 | 青岛宏致复合织造有限公司 | 提高睡眠质量的酸奶粉 |
CN107348301A (zh) * | 2017-08-24 | 2017-11-17 | 宣城华科宣木瓜生物科技有限公司 | 一种安神助眠固体饮料及其制备方法 |
-
2018
- 2018-11-05 CN CN201811309311.0A patent/CN109380723A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102961462A (zh) * | 2012-11-23 | 2013-03-13 | 西安泰科迈医药科技有限公司 | 一种用于改善睡眠、改善胃肠道功能的药物组合物及其分散片制备方法 |
CN104606294A (zh) * | 2013-11-04 | 2015-05-13 | 吉林吉春制药股份有限公司 | 一种用于健胃消食,安神利尿,同时辅助治疗胃纳不香, 睡眠不安肺结核的药物及其制备方法 |
CN104069335A (zh) * | 2014-07-17 | 2014-10-01 | 江苏东博生物医药有限公司 | 一种改善睡眠的药物组合物及制备方法和应用 |
CN105267723A (zh) * | 2014-07-23 | 2016-01-27 | 华中科技大学 | 一种具有改善睡眠功效的玛咖组方及其制备方法 |
CN105394177A (zh) * | 2015-11-11 | 2016-03-16 | 西北农林科技大学 | 一种促睡眠酸乳及其制备方法 |
CN106857825A (zh) * | 2015-12-10 | 2017-06-20 | 青岛宏致复合织造有限公司 | 提高睡眠质量的酸奶粉 |
CN106281950A (zh) * | 2016-08-18 | 2017-01-04 | 安徽天乾健食品科技有限公司 | 一种安神助眠沙棘风味果胶醋及其制备方法 |
CN107348301A (zh) * | 2017-08-24 | 2017-11-17 | 宣城华科宣木瓜生物科技有限公司 | 一种安神助眠固体饮料及其制备方法 |
Non-Patent Citations (1)
Title |
---|
田俊生等: "沙棘籽油抗抑郁作用", 《食品科学》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112167626A (zh) * | 2020-09-30 | 2021-01-05 | 内蒙古菓奇奇沙棘生物科技股份有限公司 | 一种沙棘助眠食品及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105687520A (zh) | 一种抑制脱发、白发产生且促进生发的育发液及配备方法 | |
CN102526326B (zh) | 用于治疗绝经后骨质疏松症的中药及其制备方法 | |
CN106177885A (zh) | 一种用于健胃补脾的复方发酵中药制剂及其制备方法 | |
CN111097061A (zh) | 一种安神熏香及其制备方法 | |
CN105708970B (zh) | 一种具有降血糖功能的保健食品 | |
CN105250913B (zh) | 一种治疗蛋鸡脂肪肝综合症的药物组合物 | |
CN104352552A (zh) | 一种食品、保健品或药物组合物 | |
KR20160013227A (ko) | 녹용차 제조방법 | |
CN109380723A (zh) | 一种安神助眠食品及其制备方法 | |
CN106798776A (zh) | 一种用于心悸、失眠的中成药及其制备工艺 | |
CN110973625A (zh) | 基于火麻仁的护肝醒酒组合物及其制备方法和应用 | |
CN103520302B (zh) | 一种沙棘叶抗疲劳胶囊及其制备方法 | |
CN101156688A (zh) | 一种具有调节睡眠功能的保健食品及制备方法 | |
DE202004018534U1 (de) | Kräuterzusammensetzung zur Vermeidung und/oder Behandlung von Zuständen in Verbindung mit Depression | |
CN105456566A (zh) | 一种用于治疗妇科疾病的药物及其制备方法 | |
CN104799118A (zh) | 一种狗粮及其制备方法 | |
CN104706881A (zh) | 一种具有调节睡眠功能的保健品 | |
CN101218976A (zh) | 一种改善睡眠的保健食品及其制备方法 | |
CN102462787B (zh) | 治疗高血压、改善高血脂的中药组合物及其制剂方法 | |
CN108002997A (zh) | 一种具有止呕作用的沉香提取物及其应用 | |
CN105073122A (zh) | 人参皂苷组合物 | |
CN111632074A (zh) | 一种用于治疗失眠的中西药配方及其制备方法 | |
CN104435298A (zh) | 一种抗抑郁药物组合物 | |
CN105055857B (zh) | 治疗中华鳖应激性疾病的中药制剂及其制备方法 | |
CN109549193A (zh) | 一种中药复方改善睡眠的保健食品及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |